Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sezary syndrome

被引：83

作者：

Lenihan, DJ

Alencar, AJ

Yang, D

Kurzrock, R

Keating, MJ

Duvic, M

机构：

[1] Univ Texas, MD Anderson Canc Ctr, Dept Dermatol, Unit 434, Houston, TX 77030 USA

[2] Univ Texas, MD Anderson Canc Ctr, Dept Cardiol, Houston, TX 77030 USA

[3] Univ Texas, MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

[4] Univ Texas, MD Anderson Canc Ctr, Dept Bioimmunotherapy, Houston, TX 77030 USA

来源：

BLOOD | 2004年 / 104卷 / 03期

关键词：

D O I：

10.1182/blood-2003-07-2345

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Alemtuzumab is a monoclonal antibody to CD52 that has activity in T-cell leukemia and lymphoma. This study alms to describe the complications and outcomes of a subset of patients with mycosis fungoides/Sezary syndrome who were treated with alemtuzumab. Four of 8 patients, with no prior history of cardiac problems, developed significant cardiac toxicity (congestive heart failure or arrhythmia) that mostly improved after alemtuzumab discontinuation. The role of this agent in potentially inducing important cardiac side effects is suggested and argues for further investigation.

引用

页码：655 / 658

页数：4

共 26 条

[1]

Baker AJ, 1999, J AM COLL CARDIOL, V34, P603

[2]

Coles AJ, 1999, ANN NEUROL, V46, P296, DOI 10.1002/1531-8249(199909)46:3<296::AID-ANA4>3.0.CO

[3]

2-#

[4] Severe cardiac toxicity after monoclonal antibody therapy [J].

Damaj, G ;

Rubio, MT ;

Audard, V ;

Hermine, O .

EUROPEAN JOURNAL OF HAEMATOLOGY, 2002, 68 (05) :324-324

[5] Alemtuzumab in T-cell malignancies [J].

Dearden, CE ;

Matutes, E ;

Catovsky, D .

MEDICAL ONCOLOGY, 2002, 19 (Suppl 2) :S27-S32

[6] High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H [J].

Dearden, CE ;

Matutes, E ;

Cazin, B ;

Tjonnfjord, GE ;

Parreira, A ;

Nomdedeu, B ;

Leoni, P ;

Clark, FJ ;

Radia, D ;

Rassam, SMB ;

Roques, T ;

Ketterer, N ;

Brito-Babapulle, V ;

Dyer, MJS ;

Catovsky, D .

BLOOD, 2001, 98 (06) :1721-1726

[7] Phase II study of alerntuzurnab in chronic lymphoproliferative disorders [J].

Ferrajoli, A ;

O'Brien, SM ;

Cortes, JE ;

Giles, FJ ;

Thomas, DA ;

Faderl, S ;

Kurzrock, R ;

Lerner, S ;

Kontoyiannis, DP ;

Keating, MJ .

CANCER, 2003, 98 (04) :773-778

[8] Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study [J].

Keating, MJ ;

Flinn, I ;

Jain, V ;

Binet, JL ;

Hillmen, P ;

Byrd, J ;

Albitar, M ;

Brettman, L ;

Santabarbara, P ;

Wacker, B ;

Rai, KR .

BLOOD, 2002, 99 (10) :3554-3561

[9] Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed [J].

Keating, MJ ;

Cazin, B ;

Coutré, S ;

Birhiray, R ;

Kovacsovics, T ;

Langer, W ;

Leber, B ;

Maughan, T ;

Rai, K ;

Tjonnfjord, G ;

Bekradda, M ;

Itzhaki, M ;

Hérait, P .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (01) :205-213

[10] Treatment of patients with advanced mycosis fungoides and Sezary syndrome with alemtuzumab [J].

Kennedy, GA ;

Seymour, JF ;

Wolf, M ;

Januszewicz, H ;

Davison, J ;

McCormack, C ;

Ryan, G ;

Prince, HM .

EUROPEAN JOURNAL OF HAEMATOLOGY, 2003, 71 (04) :250-256

← 1 2 3 →